Table 1 Clinical significance of RUVBL2 staining in 153 HCC patients
From: Multilevel regulation of RUVBL2 expression predicts poor prognosis in hepatocellular carcinoma
| Â | Nuclear RUVBL2 | Cytoplasmic RUVBL2 | ||||||
|---|---|---|---|---|---|---|---|---|
Negative | Weak | Strong | P value | Negative | Weak | Strong | P value | |
Age (year) | Â | Â | Â | 0.6548 | Â | Â | Â | 0.3616 |
 < 60 | 55 (53.4) | 32 (31.1) | 16 (15.5) |  | 4 (3.9) | 42 (40.8) | 57 (55.3) |  |
 ≥ 60 | 23 (46.0) | 17 (34.0) | 10 (20.0) |  | 3 (6.0) | 24 (48.0) | 23 (46.0) |  |
Sex | Â | Â | Â | 0.6956 | Â | Â | Â | 0.6332 |
 Male | 74 (51.7) | 44 (30.8) | 25 (17.5) |  | 7 (4.9) | 60 (42.0) | 76 (53.1) |  |
 Female | 4 (40.0) | 5 (50.0) | 1 (10.0) |  | 0 (0.0) | 6 (60.0) | 4 (40.0) |  |
Family history | Â | Â | Â | 0.3719 | Â | Â | Â | 0.4666 |
 Yes | 56 (52.8) | 35 (33.0) | 15 (14.2) |  | 3 (2.8) | 45 (42.5) | 58 (54.7) |  |
 No | 22 (46.8) | 14 (29.8) | 11 (23.4) |  | 4 (8.5) | 21 (44.7) | 22 (46.8) |  |
Symptomatic presentation | Â | Â | Â | 0.1776 | Â | Â | Â | 0.9539 |
 No | 54 (56.8) | 27 (28.4) | 14 (14.7) |  | 7 (7.4) | 39 (41.1) | 49 (51.6) |  |
 Yes | 24 (41.4) | 22 (37.9) | 12 (20.7) |  | 0 (0.0) | 27 (46.6) | 31 (53.4) |  |
Drinking | Â | Â | Â | 0.0316 | Â | Â | Â | 0.3927 |
 No | 59 (52.7) | 30 (26.8) | 23 (20.5) |  | 5 (4.5) | 52 (46.4) | 55 (49.1) |  |
 Infrequent | 17 (47.2) | 16 (44.4) | 3 (8.3) |  | 2 (5.6) | 11 (30.6) | 23 (63.9) |  |
 Frequent | 2 (40.0) | 3 (60.0) | 0 (0.0) |  | 0 (0.0) | 3 (60.0) | 2 (40.0) |  |
HBsAg | Â | Â | Â | 0.1774 | Â | Â | Â | 0.3722 |
 Negative | 12 (42.9) | 13 (46.4) | 3 (10.7) |  | 0 (0.0) | 14 (50.0) | 14 (50.0) |  |
 Positive | 66 (52.8) | 36 (28.8) | 23 (18.4) |  | 7 (5.6) | 52 (41.6) | 66 (52.8) |  |
Anti-HCV | Â | Â | Â | 0.9411 | Â | Â | Â | 0.4514 |
 Negative | 72 (51.4) | 44 (31.4) | 24 (17.1) |  | 7 (5.0) | 58 (41.4) | 75 (53.6) |  |
 Positive | 6 (46.2) | 5 (38.5) | 2 (15.4) |  | 0 (0.0) | 8 (61.5) | 5 (38.5) |  |
Cirrhosis | Â | Â | Â | 0.0416 | Â | Â | Â | 0.2321 |
 w/o + mild | 33 (41.3) | 33 (41.3) | 14 (17.5) |  | 3 (3.8) | 31 (38.8) | 46 (57.5) |  |
 Moderate | 23 (62.2) | 7 (18.9) | 7 (18.9) |  | 3 (8.1) | 19 (51.4) | 15 (40.5) |  |
 Severe | 22 (61.1) | 9 (25.0) | 5 (13.9) |  | 1 (2.8) | 16 (44.4) | 19 (52.8) |  |
CEA (ng/ml) | Â | Â | Â | 0.8181 | Â | Â | Â | 0.8920 |
 ≤ 5 | 72 (51.1) | 48 (34.0) | 21 (14.9) |  | 5 (3.5) | 63 (44.7) | 73 (51.8) |  |
 > 5 | 6 (50.0) | 1 (8.3) | 5 (41.7) |  | 2 (16.7) | 3 (25.0) | 7 (58.3) |  |
ALP | Â | Â | Â | 0.8388 | Â | Â | Â | 0.9196 |
 Normal | 71 (51.1) | 46 (33.1) | 22 (15.8) |  | 5 (3.6) | 61 (43.9) | 73 (52.5) |  |
 Aberrant | 7 (50.0) | 3 (21.4) | 4 (28.6) |  | 2 (14.3) | 5 (35.7) | 7 (50.0) |  |
PT(a) (%) | Â | Â | Â | 0.4977 | Â | Â | Â | 0.2135 |
 ≥ 80 | 51 (54.3) | 26 (27.7) | 17 (18.1) |  | 4 (4.3) | 36 (38.3) | 54 (57.4) |  |
 < 80 | 27 (47.4) | 21 (36.8) | 9 (15.8) |  | 3 (5.6) | 28 (30.6) | 26 (63.9) |  |
AFP (ng/ml) | Â | Â | Â | 0.2972 | Â | Â | Â | 0.1644 |
 ≤ 20 | 33 (44.0) | 26 (34.7) | 16 (21.3) |  | 4 (5.3) | 27 (36.0) | 44 (58.7) |  |
 > 20 | 41 (55.4) | 23 (31.1) | 10 (13.5) |  | 3 (4.1) | 37 (50.0) | 34 (45.9) |  |
AFP (ng/ml) | Â | Â | Â | 0.7712 | Â | Â | Â | 0.5453 |
 ≤ 400 | 57 (51.4) | 35 (31.5) | 19 (17.1) |  | 5 (4.5) | 50 (45.0) | 56 (50.5) |  |
 > 400 | 17 (44.7) | 14 (36.8) | 7 (18.4) |  | 2 (5.3) | 14 (36.8) | 22 (57.9) |  |
Differentiation grade | Â | Â | Â | 0.5340 | Â | Â | Â | 0.0016 |
 Well | 15 (57.7) | 8 (30.8) | 3 (11.5) |  | 5 (19.2) | 14 (53.8) | 7 (26.9) |  |
 Moderate | 48 (51.6) | 31 (33.3) | 14 (15.1) |  | 1 (1.1) | 44 (47.3) | 48 (51.6) |  |
 Poor | 15 (44.1) | 10 (29.4) | 9 (26.5) |  | 1 (2.9) | 8 (23.5) | 25 (73.5) |  |
Tumor size (cm) | Â | Â | Â | 0.6152 | Â | Â | Â | 0.6543 |
 ≤ 5 | 53 (52.5) | 33 (32.7) | 15 (14.9) |  | 6 (5.9) | 44 (43.6) | 51 (50.5) |  |
 > 5 | 25 (48.1) | 16 (30.8) | 11 (21.2) |  | 1 (1.9) | 22 (42.3) | 29 (55.8) |  |
Multinodules | Â | Â | Â | 0.9897 | Â | Â | Â | 0.9068 |
 No | 62 (50.8) | 39 (32.0) | 21 (17.2) |  | 5 (4.1) | 54 (44.3) | 63 (51.6) |  |
 Yes | 16 (51.6) | 10 (32.3) | 5 (16.1) |  | 2 (6.5) | 12 (38.7) | 17 (54.8) |  |
Tumor-infiltrating lymphocytes | Â | Â | Â | 0.6644 | Â | Â | Â | 0.8294 |
 No | 57 (50.4) | 35 (31.1) | 21 (18.6) |  | 6 (5.3) | 49 (43.4) | 58 (51.3) |  |
 Yes | 21 (52.5) | 14 (35.0) | 5 (20.7) |  | 1 (2.5) | 17 (42.5) | 22 (55.0) |  |
Liver capsule invasion | Â | Â | Â | 0.7086 | Â | Â | Â | 0.7920 |
 No | 48 (52.7) | 27 (29.7) | 16 (17.6) |  | 5 (5.5) | 40 (44.0) | 46 (50.5) |  |
 Yes | 29 (47.5) | 22 (36.1) | 10 (16.4) |  | 2 (3.3) | 26 (42.6) | 33 (54.1) |  |
Carcinoma cell embolus | Â | Â | Â | 0.3656 | Â | Â | Â | 0.1208 |
 No | 66 (48.9) | 45 (33.3) | 24 (17.8) |  | 7 (5.2) | 61 (45.2) | 67 (49.6) |  |
 Yes | 12 (66.7) | 4 (22.2) | 2 (11.1) |  | 0 (0.0) | 5 (27.8) | 13 (72.2) |  |
TNM staging | Â | Â | Â | 0.6785 | Â | Â | Â | 0.8315 |
 I | 55 (49.1) | 36 (32.1) | 21 (18.8) |  | 4 (3.6) | 51 (45.5) | 57 (50.9) |  |
 II | 11 (52.4) | 8 (38.1) | 2 (9.5) |  | 2 (9.5) | 9 (42.9) | 10 (47.6) |  |
 III | 9 (56.3) | 4 (25.0) | 3 (18.8) |  | 0 (0.0) | 6 (37.5) | 10 (62.5) |  |
 IV | 3 (75.0) | 1 (25.0) | 0 (0.0) |  | 1 (25.0) | 0 (0.0) | 3 (75.0) |  |
BCLC staging | Â | Â | Â | 0.4584 | Â | Â | Â | 0.3621 |
 0 | 4 (66.7) | 0 (0.0) | 2 (33.3) |  | 0 (0.0) | 3 (50.0) | 3 (50.0) |  |
 1 | 57 (47.9) | 41 (34.5) | 21 (17.6) |  | 7 (5.9) | 53 (44.5) | 59 (49.6) |  |
 2 | 12 (54.5) | 7 (31.8) | 3 (13.6) |  | 0 (0.0) | 8 (36.4) | 14 (63.6) |  |
 3 | 5 (83.3) | 1 (16.7) | 0 (0.0) |  | 0 (0.0) | 2 (33.3) | 4 (66.7) |  |